Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Public ClinicalTrials.gov record NCT04607772. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1/2, multicenter, open-label study to evaluate the efficacy, and safety of various combinations with selinexor in participants with RR DLBCL. The study will be conducted in two phases: Phase 1 and 2. The Phase 1 of the study will be a standard 3 + 3 dose escalation to determine the maximal tolerated dose (MTD), recommended Phase 2 dose (RP2D) for each treatment arm, and assess the dose limiting toxicities (DLTs). The Phase 2 of the study will be a dose expansion study to assess the efficacy and safety of for RP2D selected at the end of Phase 1 of the study for each treatment arm.
Study identification
- NCT ID
- NCT04607772
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- Not listed
Conditions and interventions
Interventions
- Selinexor Drug
- Rituximab Drug
- Bendamustine Drug
- Polatuzumab Vedotin Drug
- Ibrutinib Drug
- Lenalidomide Drug
- Tafasitamab Drug
- Venetoclax Drug
- Gemcitabine Drug
- Oxaliplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2020 (Actual)
- Primary completion
- Dec 2025 (Estimated)
- Completion
- Dec 2025 (Estimated)
- Last update posted
- Oct 3, 2025
2020 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona | Tucson | Arizona | 85724 | — |
| California Cancer Associates for Research and Excellence | Encinitas | California | 92024 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| University of California Irvine | Orange | California | 92868 | — |
| US Oncology - Rocky Mountain Cancer Center | Aurora | Colorado | 80012 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Mission Cancer + Blood | Des Moines | Iowa | 50309 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48021 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | — |
| US Oncology - Oncology Associates of Oregon | Eugene | Oregon | 97401 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| US Oncology - Prisma Health | Greenville | South Carolina | 29605 | — |
| US Oncology - Texas Oncology Austin Midtown | Austin | Texas | 78705 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| Baylor Clinic - Mcnair Center | Houston | Texas | 77030 | — |
| US Oncology - Northwest Cancer Specialists | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04607772, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04607772 live on ClinicalTrials.gov.